PTC Therapeutics, Inc. Contract Liability (Deferred Revenue)
PTC Therapeutics, Inc. (PTCT) had Contract Liability (Deferred Revenue) of $1.19 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-07-30
- 2026-06-30: Contract with Customer, Liability, Current $1.19M.
- 2026-03-31: Contract with Customer, Liability, Current $498.00K.
- 2025-12-31: Contract with Customer, Liability, Current $2.04M.
- 2025-09-30: Contract with Customer, Liability, Current $1.69M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $1.19M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $498.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.04M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $1.69M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $9.76M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $12.83M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $5.50M 10-K · filed 2026-02-19 |
| 2023-12-31 | $801.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.22M 10-Q · filed 2023-10-26 |
| 2023-03-31 | $214.00K 10-Q · filed 2023-04-27 |
| 2022-12-31 | $1.35M 10-K · filed 2024-02-29 |
| 2021-06-30 | $0.00 10-Q · filed 2021-07-29 |
| 2021-03-31 | $1.89M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $4.15M 10-K · filed 2022-02-22 |
| 2020-09-30 | $5.99M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $7.70M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $8.64M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $8.24M 10-K · filed 2021-02-25 |
| 2019-09-30 | $8.81M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $8.01M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $5.50M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $3.72M 10-K · filed 2020-03-02 |
| 2018-09-30 | $2.00M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-07 |
| 2017-12-31 | $3.94M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |